Eli Lilly raised its outlook for a third time this year thanks to soaring Zepbound sales
Lilly's revenue guidance rises to $91 billion to $92 billion from $85 billion to $87 billion as quarterly sales climb 39%
We haven't written up this one. Quartz has the full story — the link below goes straight to it.